LMB-2

N/A

Report date: 2026/05/05 20:00:16

Base Information

Drug NameLMB-2
Drug Alias Namealpha Tac-Fv-M18-PE24AntiTac(Fv)-PE38LMB-2LMB-2a
ClassificationBiologics > Protein drugs > ToxinBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody murine
Mechanisms of ActionInterleukin-2 receptor alpha chain inhibitors
TargetsInterleukin-2 receptor alpha chain
Therapy Area/IndicationsSkin MelanomaMyeloproliferative DisordersMyelodysplastic Syndromes +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesNational Cancer Institute
China Registration ClassN/A

Develop Information

Active CompaniesNational Cancer Institute
Inactive CompaniesNational Institutes Of Health Clinical Center (Cc)Yale University
Active IndicationsLeukemia, Hairy Cell
Inactive IndicationsSkin MelanomaMyeloproliferative DisordersMyelodysplastic Syndromes +[8] 

Other Information

ATC CodeN/A
Related LinksN/A